Braintree founder Bryan Johnson and USC researcher team up on Kernal, a startup building a chip implanted in brains to help people with neurological damage
Elizabeth Dwoskin / Washington Post :
Context & Ripple Effects
Bryan Johnson is taking money made in payments infrastructure — he founded Braintree — and pointing it at neurotechnology, pairing with a USC researcher to build an implantable chip aimed at neurological damage. The move puts him at the front of a wave that includes chip designers entering the field: ARM later partnered with University of Washington researchers on neural implant chips for brain and spinal injuries.
The arc since this founding story shows how hard the medical-implant path is: by 2020 Kernel had raised a $53M Series C around 'Neuroscience as a Service' brain-imaging devices rather than implants, while newer entrants like Precision Neuroscience, co-founded by a Neuralink co-founder, raised $41M betting on less invasive hardware.
First-order effects
- Patients with neurological damage gain a well-funded new research effort targeting implantable treatment, backed directly by Johnson's Braintree fortune rather than traditional medtech or NIH channels.
- USC gains a flagship commercial-neuroscience partnership that anchors its lab work to a startup vehicle instead of grant-funded research alone.
Second-order effects
- Chip suppliers see a new demand pool: ARM's University of Washington collaboration signals semiconductor firms positioning to sell silicon into implants rather than ceding the layer to startups designing their own.
- Rivals calibrate against Kernel's invasive approach — Precision Neuroscience's later raise shows investors funding explicitly less invasive alternatives, splitting the market along invasiveness lines.
Third-order effects
- If the pattern holds, founder-scale personal capital keeps seeding neurotech companies whose business models migrate toward services and measurement (as Kernel's own shift toward imaging suggests), concentrating the field among a few heavily capitalized players while pure implant plays stay capital-hungry and slow.
The trend: Tech-founder wealth is becoming the primary funding source for brain-interface startups, pushing the field to waver between medical implants and commercialized neuroscience services.